Table 2.
Systemic conditions and classes of ant‐hypertensive drugs using in patients with CKD patients
| Systemic conditions in 200 CKD patients | |
|---|---|
| Etiology of CKD, n (%) | |
| DM | 75 (37.5) |
| Hypertension | 49 (24.5) |
| Gout | 11 (5.5) |
| Other systemic diseases | 7 (3.5) |
| Chronic glomerulonephritis | 25 (12.5) |
| Polycystic kidney disease | 9 (4.5) |
| Other renal or urinary tract diseases | 11 (5.5) |
| Unknown etiology | 13 (6.5) |
| CKD stage, n (%) | |
| Stage 3 | 81 (40.5) |
| Stage 4 | 43 (21.5) |
| Stage 5 | 76 (38.0) |
| Treatments, n (%) | |
| Hemodialysis | 27 (13.5) |
| Peritoneal dialysis | 33 (16.5) |
| Kidney transplantation | 3 (1.5) |
| Creatinine (mg/dL), mean ± SD | 4.68 ± 4.37 |
| eGFR (mL/min/1.73 m2), mean ± SD | 26.9 ± 19.8 |
| Classes of drug in 176 CKD patients using anti‐hypertensive drug(s), n (%) | |
|---|---|
| ACEI/ARB | 128 (73) |
| Calcium channel blockers | 87 (49) |
| Beta‐blockers | 75 (43) |
| Diuretics | 51 (29) |
| Alpha‐1 blockers | 17 (10) |
| Vasodilators | 9 (5) |
| Alpha‐2 agonists | 2 (1) |